1 / 19

Treatment Pathways for Carcinoma of the Pancreas

Treatment Pathways for Carcinoma of the Pancreas. Metastatic Unresectable, not metastatic Resectable. Treatment Pathways for Carcinoma of the Pancreas. Metastatic cancer. GTX Chemotherapy for Pancreatic Cancer.

job
Download Presentation

Treatment Pathways for Carcinoma of the Pancreas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment Pathways for Carcinoma of the Pancreas Metastatic Unresectable, not metastatic Resectable

  2. Treatment Pathways for Carcinoma of the Pancreas Metastatic cancer

  3. GTX Chemotherapy for Pancreatic Cancer Robert L Fine, William Sherman, John Chabot, Stephen Schreibman, Michael Williams, Michael Cusnir, David Van Echo, Columbia Universirty, College of Physicians and Surgeons, New York, NY; University of Virginia, Charlottesville, VA; University of Maryland, Baltimore, MD.

  4. Hypothesis PC cells frequently have ras and p53 mutations that block certain apoptosis pathways. Chemotherapy drugs should be screened in vitro against cell lines with ras and p53 mutations.

  5. In vitro findings: There is synergism between 5-FU and gemcitabine and between gemcitabine and taxotere. Synergism between gemcitabine and taxotere was observed at nanomolar concentrations of taxotere.

  6. In Vitro Schedule-dependent Interaction between Docetaxel and Gemcitabine in Human Gastric Cancer Cell Lines Luca Ricotti, Anna Tesei, Franca De Paola, Paola Ulivi, Giovanni Luca Frassineti, Carlo Milandri, Dino Amadori and Wainer Zoli Clinical Cancer Research Vol. 9, 900-905, February 2003 Doc + Gem Gem  Dox Dox  Gem

  7. GTX Xeloda 1500 – 2000 mg/m2/day in 2 daily doses, Day 1 – 14 Gemcitabine 750 - 1000 mg/m2 i.v. over 2 hours, Day 4, 11 Taxotere 30 mg/m2 i.v. Day 4, 11 Fine, Sherman, et al. ASCO 2002, p144a, abstract #575

  8. GTX 24 patients with metastatic tumor: PR 50% SD 25% NR 25% Fine, Sherman, et al. ASCO 2002, p144a, abstract #575

  9. Other protocols for metastatic carcinoma of the pancreas Cis-platinum + irinotecan Cis-platinum + gemcitabine

  10. Treatment Pathways for Carcinoma of the Pancreas Unresectable, not metastatic

  11. Downstaging patients with locally advanced, non-metastatic tumor • 8 patients with locally advanced tumor treated with GTX -> Radiation + weekly Gemcitabine -> Surgery: • 5 had Whipple with negative margins and normal post-op CA 19-9 Fine, Sherman, et al. ASCO 2002, p144a, abstract #575

  12. Treatment Pathways for Carcinoma of the Pancreas S/p resection, no known residual or metastatic tumor

  13. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma External beam radiation 4,500 cGy to 5,400 cGy, 25 fractions in 5 weeks Cis-platinum 30 mg/m2 once a week 5-FU 200 mg/m2/day continuous i.v. infusion a-interferon 3 x 106 u sq every other day Followed by continuous i.v. 5-FU weeks 9  14 and 17  22 Nukui, Picozzi, Traverso. Am J Surg 2000; 179: 367-71

  14. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma Between 1993 and 1998 33 patients at VMMC, Seattle WA had adjuvant therapy with a) “GITSG” bolus 5-FU and radiation or b) “IFN based” chemoradiation Not a randomized trial Comparable stage and prognostic factors in both groups Nukui, Picozzi, Traverso. Am J Surg 2000; 179: 367-71

  15. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma Nukui, Picozzi, Traverso. Am J Surg 2000; 179: 367-71

  16. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma 26 month median follow-up: 2-year survival GITSG style 54% IFN-based 84% Nukui, Picozzi, Traverso. Am J Surg 2000; 179: 367-71

  17. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma Audit and update by committee from ACOS: 53 patients treated at VMMC analyzed with adjuvant “Ifn-based” chemoradiation and 5-FU after Whipple 49% 5-year survival

  18. Interferon-based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma 70% required treatment delay 43% required hospitalization 90% received full dose of radiation 85% received full dose of chemotherapy

  19. ACOSOG Z5031 - Phase II Study Eligibility: R0 or R1 resection T 1 - T3, N0 - N1, M0 Adenocarcinoma of head of pancreas Changes in treatment compared to VMMC study: 175 mg/m2/day 5-FU instead of 200 mg/m2/day 5040 cGy in 28 fractions - 180 cGy fractions instead of 200 cGy fractions

More Related